Lanque signed a tripartite strategic cooperation agreement with Fudan University and Watson Biology. As an investor, God Asset witnessed a milestone moment in the development of Lanque.
Recently, Fudan University, Yunnan Watson Biotechnology Co., LTD. (hereinafter referred to as Watson Biology) and Shanghai Lanque Biomedical Co., LTD. (hereinafter referred to as Lanque Biology) signed a tripartite strategic cooperation agreement in Handan Campus of Fudan University.Lin Jinzhong, director of the mRNA Drug Transformation Center of Fudan University, Li Yunchun, chairman of Watson Biological, and Yu Hang, chairman of Blue Que Biological signed the cooperation agreement on behalf of the three parties.
▲ tripartite strategic cooperation signing ceremony (seventh from left is President Jin Li, Chairman Zhong Bin, sixth from left, President Lin Xinhua, eighth from left, and Director Zhang Wenhong, ninth from left)
Fudan university school of life sciences dean Lin Xinhua presided over the signing ceremony, Chinese academy of sciences, President of fudan university, Zhang Wenhong, director of the national center for infectious disease medicine, fudan university, vice President of the university enterprise leaders participated in the signing ceremony, xi god assets chairman Zhong Bin and China state-owned capital risk investment fund, the Chinese Academy of Sciences and fund blue magpie biological investors representatives also attended and witnessed the agreement signed.
Industry-university-research cooperation has accelerated the development of blue Que mRNA vaccine
▲ Jin Li, Academician of Chinese Academy of Sciences and President of Fudan University
At the signing ceremony, Academician Jin Li, president of Fudan University, said that Fudan University, as a famous university with a history of 117 years, should not only comprehensively improve its scientific research level, but also practice its national strategic mission and accelerate the transformation of achievements.Lanque Biology and Watson Biology have unique advantages in mRNA drug research and development and vaccine commercialization, respectively. The cooperation between the three parties in the COVID-19 project is fully in line with the development direction of Fudan's integration and innovation, and reflects the university's determination to accelerate the transformation of achievements.In the future, the three parties can expand their cooperation areas and deepen their cooperation in AI drug design, medical clinical practice and talent training.President Jin is full of confidence in the cooperation between the three parties.
▲ Lin Jinzhong, director of the mRNA Drug Transformation Center, Fudan University
Professor Lin said, under the leadership of fudan university, biology and research institute support, fudan university mRNA discipline construction has been rapid development, has supported the construction of the "mRNA drug transformation center" and Shanghai "zhangjiang mRNA international innovation center", and won the Ministry of Science and Technology and Shanghai founded strong support.Lin also highlighted the latest progress of the mRNA vaccine. Animal trials and clinical IIT studies showed that the mRNA vaccine showed the efficacy and safety of the mutant strain, including the Oikong mutant strain.With the joint efforts of Lammagpie Bio and Watson Bio, the vaccine is expected to commercialize its products soon.
▲ Zhang Wenhong, Director of the National Center for Infectious Diseases Medicine and professor of Fudan University
Zhang Wenhong, director of the National Medical Center for Infectious Diseases, also affirmed the important strategic significance of the signing.Professor Zhang Wenhong believes that in the face of COVID-19, it will be difficult to overcome the epidemic without a vaccine. Professor Lin Jinzhong's accumulation and breakthrough in mRNA vaccine development are of great significance to overcoming all human diseases including COVID-19.Zhang also expects that with the efforts of the three parties, the IRC-developed mRNA vaccine will enter clinical research as soon as possible to improve China's comprehensive capability for epidemic prevention and control; and the cooperation will bring more transformation results.
▲ Li Yunchang, chairman of Watson Biology
Li Yunchun, chairman of Watson Biology, also comprehensively introduced its advantages and experience in vaccine commercialization.Watson's team has more than 40 years of experience in vaccine development. Watson has the second largest number of batches in China, and Watson has deployed three technical routes in the new coronavirus field according to international standards.Chairman Li Yunchun believes that the mRNA vaccine being promoted with Fudan and LanQue is an efficient and safe COVID-19 vaccine in step with the international advanced level and will become a strong guarantee for the national epidemic prevention and control.Mr.Li also believes that based on the mutual recognition and sincere cooperation of Fudan University, Blue Que Biology and Watson Biology, there will be more extensive cooperation in the future to realize the comprehensive application of mRNA technology in the field of vaccine.
Enabling investment will help more Biotech companies grow
This is a landmark strategic cooperation agreement.The three parties have expressed strong recognition and good expectations for this strategic cooperation.Three parties will play their in basic research, drug research and development and clinical industrialization of experience and technical advantages, establish close, long-term and harmonious strategic cooperation, realize technology resource sharing, complementary advantages, jointly promote "will be coronavirus mRNA vaccine" development and commercialization, strengthen the integration, provide continuous support for mRNA vaccine development, positive contribution to the global fight against new outbreak, make scientific research results early serve national disease resistance.
▲ Yu Hang LanQue biological chairman
Blue magpie biological chairman YuHang said the domestic mRNA technology and pharmaceutical industry is very weak, blue magpie biological back by fudan university deep research background, the academic influence and medical ecosystem, combined with rich industry experience of Watson biological, is facing excellent development opportunities, blue magpie has been in Shanghai Baoshan and jiangwan, Zhejiang Shaoxing and other places established the research and development base, comprehensively promote each mRNA vaccine and drug pipeline research and development.Chairman Yu Hang is full of confidence in the launch of Lanque Bio's COVID-19 vaccine, and believes that Que, Fudan University and Watson will be closer in the future, and can quickly respond to the complex changes in the global COVID-19 situation, thus providing important support for the national epidemic prevention and control.
The parties also had in-depth exchanges on the establishment of joint laboratories under the strategic cooperation system, jointly applying for national innovation and industrialization projects, and carrying out clinical medical research on infectious diseases in the future, and hoped that the tripartite industry-university-research cooperation will make more and greater contributions to China's epidemic prevention and control.
As an investor, Xishen Asset is sincerely happy with the cooperation between the three parties, and also looks forward to providing better assistance for the development and commercialization of Lanque Biological related vaccine products under the close cooperation between industry, university and research institutes.During this visit to Shanghai, Chairman Zhong Bin also went to Baoshan District and had an in-depth discussion and exchange with relevant government leaders of Baoshan District on the investment and development cooperation of bio-pharmaceutical technology enterprises (Biotech).
As a professional investor of life and Health track, Xishen Asset has invested in dozens of R & D and growth enterprises at home and abroad, and established the whole-industry life cycle investment process. Relying on excellent industrial capital and expert resources, it will continue to empower investment enterprises.